Company / Operating Income per Share
Spero Therapeutics, Inc. Operating Income per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$1.34
FY2025
5-year range
-$2.72 / $0.41
FY2021-FY2025
Trend
-431.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income per Share changed -432% YoY in FY2025, a notable deviation from the 7-year average annual change of -33%.
Based on SEC 10-K filings.
-1.34 in FY2025.
Declined from $-0.80 to $-1.34 over the past 2 years.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income per share decreased 431.5% year-over-year.
- Peak operating income per share was recorded in FY2024.
- Lowest operating income per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.34 | -431.5% |
| FY2024 | $0.41 | +150.4% |
| FY2023 | -$0.80 | +70.4% |
| FY2022 | -$2.72 | -0.4% |
| FY2021 | -$2.70 | +17.9% |
| FY2020 | -$3.29 | -32.4% |
| FY2019 | -$2.49 | -7.6% |
| FY2018 | -$2.31 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026